On December 5, 2022, Debra Zack, M.D., Ph.D., the Company’s Chief Medical Officer, was removed from her position and her employment terminated in connection with the Reduction in Force.
On December 5, 2022, Mark Hazeltine, the Company’s current Chief Operating Officer was appointed to serve as the Company’s Chief Business Officer.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
Debra Zack was terminated as Chief Medical Officer at EXAGEN INC..
Action
terminated
Role
Chief Medical Officer
Exact text from the filing
On December 5, 2022, Debra Zack, M.D., Ph.D., the Company’s Chief Medical Officer, was removed from her position and her employment terminated in connection with the Reduction in Force.
EXAGEN INC. announced a restructuring with charges of approximately $750,000 (42 employees).
Type
restructuring
Charge
approximately $750,000
Headcount
42 employees
Exact text from the filing
On December 5, 2022, the Board of Directors of Exagen Inc. (the “Company”) approved a reduction in force intended to conserve the Company’s current cash resources. The Company will reduce its current workforce by 42 employees (the “Reduction in Force”). The Company estimates that it will incur aggregate pre-tax charges of approximately $750,000 in connection with the reduction in force, primarily consisting of notice period and severance payments, employee benefits and related costs.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.